Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, while Novo’s cautious marketing lagged behind Lilly’s aggressive, ...

Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk shares fell significantly due to pressure from U.S. President Donald Trump to cut drug prices, and competition ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.